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Abstract 
Microelectrodes today and nanoelectrodes tomorrow further studies in fields of 
science such as neurobiology and electrophysiology, and are already in use as 
neural prosthetics. When electronic devices are used in biomedicine, especially 
when needed for chronic implantation, their ongoing downscaling is largely 
motivated by two aspects: biocompatibility and specificity. It has been shown that 
downscaling is a way to significantly decrease the damage done by such devices.  
In the research and development of new, complex devices, these need be 
continuously evaluated in various ways. In vivo experiments are one necessary 
part, and in vitro cell cultures are far from a complete substitute to an entire 
animal, but they constitute a very useful model nonetheless. There are three main 
drawbacks to in vivo testing: the cost, the complexity of the living organism – 
which can be an obstacle in routine tests – and animal suffering – the main reason 
why animal testing should only be used if there is no other sufficient option.  
Consequently, cell cultures can be much more appropriate in some instances. 
The aim of this project was to set up a quick-stop in vitro test station at which 
different electrode designs can be tested against one another. An existing setup 
originally assembled for patch clamp experiments was used with cell cultures 
chosen for other experiments primarily. PC12 cells and later mouse cortical 
neural stem cells were stimulated with KCl to produce action potentials. For PC12 
cells no action potentials were registered, and for the cortical stem cells the 
consistency sought was not achieved. It is possible that this setup, using cortical 
stem cells, can achieve the intended practical use, but this project cannot assess 
this finally. 
Abbreviations 
AP – Action Potential 
BMI – Brain Machine Interface 
CNS – Central Nervous System 
DBS – Deep Brain Stimulation 
EEG – Electroencephalography  
MP – Membrane Potential 
NGF – Nerve Growth Factor 
NRC – Neuronano Research Centre 
PD – Parkinson's Disease 
PLL – Poly-L-Lysin 
VGCC – Voltage-Gated Calcium Channels 
NB: PC12 is a designated name, not an abbreviation. 
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1. Introduction 
The role of nanoscience in biomedical engineering is increasingly one of concrete 
utility over abstract concept; science rather than science fiction; and real more 
than ideal. The nanoscale has much to offer, but many challenges are inevitably 
involved when working on a scale largely too small for us to directly interact with 
– making us even further dependent on our tools, practices and theories than 
within the macro- or indeed microscale. Yet the field’s enticing potential 
continuously drives research and development.  
As our base of knowledge grows and cross-scientific projects and collaborations 
enhance the foundations of much half excavated understanding, along with the 
emergence of new tools and improved equipment, the boundaries of what we 
perceive as achievable are continuously pushed back. Within the broad scope of 
nanoscience, electronic devices find their place and application in biomedicine. 
Electrodes can be used for communicating with neurons in living organisms, both 
to the end of stimulating adjacent neurons and to gather information from the 
living environment, to the benefit of many adjacent scientific disciplines.  
Microelectrodes today and nanoelectrodes tomorrow further studies in fields of 
science such as neurobiology, where they increase our understanding of 
increasingly specific aspects of the single neuron or the central nervous system 
(CNS). In electrophysiology they find themselves put to obvious use, and 
nanoelectrodes have already played an important role as electrical or chemical 
sensors. One might, for example, use them as amperemeters or voltammeters to 
observe (changes in potential at) and study exocytosis (the process of neural 
transmitter release).[1] 
When referring specifically to brain-machine interfaces (BMIs, alternatively 
named brain-computer interfaces, or sometimes (cortical) neural prosthetics) used 
for example in deep brain stimulation (DBS), the ongoing downscaling of the 
apparatuses involved is largely motivated by two aspects: biocompatibility and 
specificity. It has been shown that downscaling is a way to decrease (sometimes 
drastically) the damage done by such devices, though it is not the only important 
aspect (others include surface structure, shape, rigidity).[2,3]  
In constructing neural probes, reducing damage from the implant is one of the 
major challenges – and one of the major subjects of research at the Neuronano 
Research Center (NRC), among other places. The NRC has the explicit view that 
“The goal of NRC is to develop highly advanced BMI that will enable us to 
record and/or stimulate hundreds or more neurons with a high spatial and 
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temporal resolution in freely moving animals. As these electrodes are meant to be 
implantable in animals and later on in humans for long periods of times, they need 
to be fully biocompatible, i.e. ‘tissue friendly’”.[4] Nanowires might have the 
added benefit of being biodegradable (to some extent). That is, if a nanosize 
semiconductor wire – a part of a larger BMI complex – breaks off from its 
substrate, the brain's normal defense mechanisms might handle the alien matter, 
reducing it to small, containable and removable fragments.[5] This is a very 
useful step towards complete biocompatibility and reduced medical concerns 
about chronic neural implants. Especially since biodegradability achieved by 
choosing a material specifically for that aspect might be more likely to be 
degraded also when and where it should not be (i.e. when working at its intended 
site). This degradation of implants over time is another issue when developing 
chronic implants.[6] 
To meet the new or improved requirements, novel materials are sometimes 
chosen. One prolific example is a material used in BMIs at the NRC: the negative 
resist SU-8. Beyond its biocompatibility, the relative ease of manipulation (by 
UV-light, neglecting more advanced and expensive techniques) is lauded, and 
wherefore it has conventionally been used as a pattern transfer substance. But the 
material also has low Young's modulus (i.e. it is flexible), high chemical 
resistance (durable in a biological environment), is transparent in the visible 
spectrum and has dielectric properties (offers some interesting possibilities for 
fine manipulation). At the NRC, SU-8 has seen use together with gold leads to 
create a flexible multielectrode BMI intended for recording in the 
cerebellum.[7,8] 
To reduce the tissue response from electrodes, one might also opt to improve the 
implantation method. At the NRC, gelatin embedding has shown promise both in 
reducing the tissue damage at implantation and at protecting small, sensitive 
electrodes at that crucial stage. The gelatin will also provide protection from 
degradation (both from mechanical stress and the biochemical environment) over 
time.[3] 
Naturally, the more and more distinguished ability to in detail control the 
production of these devices is tantamount to practical advance. While BMIs are 
unlikely to become a simple, low-cost solution to mundane diseases or conditions 
– largely because of the cost and risk of human neurosurgery – the ability to 
produce the devices as effectively as possible need be developed for BMIs to 
become a more prominent occurrence on treatment level.  
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But to what extent are BMIs a real treatment option today? Well, DBS electrodes 
have been implanted for decades now, and mechanical limbs exist, though still 
rare. Cochlear implants are another type of neural interfaces which has achieved 
mainstream medical acceptance, although they are not CNS implants.[6] The 
following part will try to provide picture of where we stand today.  
1.1. Deep Brain Stimulation Today 
DBS surgery has been performed in over 75'000 people worldwide (as of 2010 [9] 
– 40'000 in 2008 [10]), and has been shown to be an effective treatment for 
Parkinson's disease (PD), essential tremor, dystonia and obsessive compulsive 
disorder, conditions for which DBS is a treatment approved by the United States 
Food and Drug Administration.[9,10] Indications exist that DBS can find further 
use in epilepsy, depression, Tourette's syndrome, chronic pain and more.[9,10,11] 
In addition, connecting neural implants to external robotic manipulators might 
allow people to regain lost muscle control, or to control entirely prosthetic limbs 
or some device (e.g. a wheelchair). In an optimistic future, ALS patients are able 
to walk and amputees regain all but the finest touch.[6,12]  
While we are far from such perfection, the current applications are not essentially 
different; merely noticeably imperfect. Prosthetic limbs that obtain their 
commands from either non-invasive (e.g. electroencephalography (EEG) 
recording from the surface of the head – a method with distinct restrictions, 
largely concerning discernability and depth of recording; not to mention that EEG 
is for recording only – or functional magnetic resonance imaging, which is much 
too cumbersome to be of everyday use) or invasive neural recordings do exist, 
though they are very expensive – in production and in implementation; requiring 
extensive, laborious efforts from both patient and doctor to be made useful – and 
thus, tragically, unlikely to be readily available in the near future.[9,10] They are 
also far from a perfect substitute to our exceedingly complex biological body 
parts. When looking to improve control – in any BMI-application – invasive 
methods prevail, and furthering the surgical techniques and the implants' 
characteristics are necessary steps toward making BMIs less exotic.[9,12] 
Arguably, the more effective the final product is, the more likely production costs 
and implementation methodology will be (of interest to be) optimized. 
A significant and possibly imminent change could be the development of closed- 
rather than open-loop BMIs. A closed-loop BMI would not require the 
abovementioned, meticulous – often trail-and-error – manual adjustment long 
subsequent to implantation, but instead relies on incorporated continuous 
feedback systems and the input from the patient. Most importantly, the closed-
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loop BMI reacts to its real-time environment, not to the calibrated and presumed 
state. Trails in primates are ongoing, and closed-loop hard- and software is being 
developed. It might be necessary – not merely desirable – for a closed-loop BMI 
to include chemical as well as electrical sensors, to better act as one with its 
neural environment.[9,13] 
While DBS implants have traditionally been of the millimeter or hundreds of 
micrometer scale, the benefit of having smaller electrodes (and more complex 
BMIs) is well documented. Among the several advantages are higher specificity 
and less tissue damage, with fewer and lesser side effects deriving from both 
previous aspects, and concerning both the short and the long term. In addition, the 
inflammatory response appears to increase the risk of autoimmune disease later 
on (including but not limited to Alzheimer’s disease); further reason to avoid or 
reduce it as far as possible.  
At the NRC, much effort is dedicated to addressing these issues; partially in 
developing new electrodes (smaller, new structures, bio-friendly materials), and 
partially in focusing on the overall design of the implanted components (including 
anchoring and transmitter).  
Biocompatibility is most important for chronic implants, where a foreign object 
over time will give rise to normal but disruptive tissue responses, such as 
inflammation, scarring and neural rerouting. One of the most widely 
acknowledged concerns with traditional, macro-scale DBS electrodes is the glial 
scarring that develops around the implant over time. Even with improving 
surgical procedures, the implantation itself will give rise to some scarring, but not 
– today – an amount which cannot be accepted, and worked “around.” However, 
the scarring worsens over time, especially for larger, stiffer electrodes, although 
indications are that the anchoring mechanism might be almost as important as the 
BMI itself. With every movement and every breath – indeed, with every heartbeat 
– the brain moves ever so slightly, seen from the macro-scale; movements which 
rub the living tissue against the rigid electronic device, damaging and irritating 
the tissue and giving rise to its protective responses. To the electronics, the glial 
scarring is the most prominent response. Glial scarring twice decreases the effect 
of the implant; firstly as the glial cells replace neurons (possibly damaged or 
dead) from which one would record, secondly as they constitute isolation to and 
from the neurons beyond.[2] 
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1.2. A Clinical Example; Parkinson's Disease 
PD is a prominent example when discussing practiced DBS. This is largely due to 
the comparatively specific location of the disease. PD is characterized (primarily) 
as neurodegeneration in the substantia nigra (especially the pars compacta 
region), with a loss of dopaminergic motor control neurons (innervating the basal 
ganglia). Pharmacologically elevating the levels of dopamine at the site is yet the 
prevailing treatment. Because the blood-brain barrier does not let dopamine itself 
past, the precursor L-dopamine (levodopa) is administered. However, the 
systemic administration causes elevated levels throughout the body (albeit 
suppressed with co-administered substances) and in the CNS (where those co-
administered substances cannot – and should not – go). The elevated levels cause 
a number of side effects, of both systemic and CNS origin; including but not 
limited to nausea and dyskinesia (involuntary, “faulty” movement; increasing 
over time).[14] 
Early surgical approaches to PD included (irreversibly) lesioning parts of the 
brain. In Lund in 1960 for example, Svennilson et alia developed a procedure for 
pallidotomy (lesioning at globus pallidus, GPi). While these methods were 
variably effective in removing PD tremor, the side effects were often severe – 
mainly relating to motor control – and akinesia and rigidity from PD 
prevailed.[10,11] 
For PD, DBS uses high-frequency pulse trains of up to 200Hz, and was all but 
stumbled upon in 1987.[15] Since then, the target areas have been the same few, 
which has allowed for some practice, and has inferred understanding about the 
proximate areas of the brain (partially due to observing side effects). Today, using 
DBS, the subthalamic nucleus (alternatively the ventrointermediate nucleus (for 
tremor symptoms only) or possibly the GPi (for which similar direct results have 
been recorded, yet secondary and side effects need be further investigated)[11]) is 
often recognized as the point of interest: a small cluster of specific glutaminergic 
neurons found below the thalamus. However, for all neurodegenerative conditions 
– even the relatively limited and straightforward PD – the mechanisms are not 
entirely clear, and alternative theories for the mechanisms of action exist. Beyond 
the prevailing major hypothesis – silencing of hyperactive (due to lack of 
inhibiting nervous activity) neurons – several complementary systems (some of 
which are directly contradictory) might or might not be involved, to degrees of 
importance not easily determined.[11,14] The complexity of the system(s) 
involved is awe-inspiring. 
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Because of the complexity of the situation, undesired effects do arise. One not 
uncommon side effect of conventional DBS for PD is speech impediment 
(dysarthria), believed to be connected to breathing muscle control (which give 
rise to fears of worse possible side effects). There are also cases where DBS is 
believed to have been directly responsible for depression, even to a suicidal level. 
Obviously undesirable, such side effects are largely hoped to disappear with 
higher spatial specificity in stimulation.[11,14]  
Side effects become more and more difficult to avoid with progressing glial 
scarring around the DBS electrode (largely because specificity is lost, and 
unwanted areas stimulated). Thus, this is an area where smaller electrodes have 
greater appeal. Microelectrodes have the ability to stimulate a small volume of 
quite specific nerve cells, whereas nanoelectrodes can stimulate a single neuron, 
and could potentially – using an array of electrodes with different functions – 
exert control even greater than 1:1 neuron-electrode interaction.[1,2,5]  
It might be worth noting that neural implants are not necessarily a competitor to 
conventional pharmaceuticals, but rather a compliment. PD is still a good 
example, and indeed; it is commonplace to treat the disease with complementary 
implant and pharmaca whenever possible. Among the reasons for this is a 
limitation of the implant: in contrast to the advantages of the highly specific 
neural implant, it will not – unlike what is desired and to some extent achieved 
with drug therapy – protect from disease propagation (unless the resumption of 
normal function in specific, targeted areas offer such effects secondarily (possibly 
the case with neurodegeneration)).[11] But even if DBS and neural prosthetics 
cannot fully take the place of pharmaceutical treatment, possible lowered drug 
doses could help minimize side effects from the pharmaca.[11,14] One may well 
hypothesize that future combinations of compensatory or interfering DBS 
together with pharmaceutics intended to retard or retract disease propagation 
might prove widely effective, in more cases than PD. 
A side note: another use of nanotechnology in PD (or indeed most neural 
diseases, as well as others) is in constructing biochemical transport vessels which 
allow drugs to cross (more readily or at all) the blood brain barrier. This too 
lowers side effects – systemically – as lesser amounts of a drug is needed to give 
the correct concentration at the site of action, potentially all but completely 
removing certain (in CNS conditions: systemic ones) side effects.[6] 
If the use in PD is relatively straightforward, then the use of DBS and chronic 
implants in the treatment of psychological conditions is far more controversial. 
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Advocates sometimes say the ethical issues are not intrinsically distinct from 
those faced by pharmacological treatments; for which clear guidelines exist. And 
in major depressive disorder, for example, its use has been approved in severe 
cases unresponsive to pharmacological treatment. A lot of the concern centers on 
the concept of personality alteration and the forced divergence from a “true self”, 
a very complex issue, naturally.[16] More outlandish (or even paranoid concerns) 
include fears that neural implants could be used for sinister mind-control 
purposes, or that brain-enhancement will constitute the foundation for a distinct 
rift between rich “superhumans” and their subjects.[17] While such objections 
might not be directly relevant to the scientific process, a lot of concern about the 
ethical implications (and indeed public fears, substantial or not) of emerging 
scientific disciplines, along with how they are researched, must be taken. 
 
1.3. On in vivo and in vitro 
Ethical concerns can be a strong argument for setting up cell cultures. There are 
three main drawbacks to in vivo testing: the cost, both direct and indirect, as 
animal facilities and handling are both costly, the complexity of the living 
organism which – while it is naturally necessary to accept and work in accordance 
with – can be an obstacle in more routine tests, and animal suffering. Animal 
testing should only be used if there is no other sufficient option – especially 
important if tests are intended to be continuously repeated. So while in vitro cell 
cultures are far from a complete substitute to an entire animal, they nonetheless 
constitute a very useful model which in some instances is much more appropriate. 
 
1.4. On the PC12 Cell Line 
PC12 cells are a cell line derived from the pheochromocytoma – a nuroendocrine 
tumor – of the rat adrenal medulla. The cell line is capable of differentiating into 
either adrenal chromaffin-like cells – neuroendocrine endothelial-like cells – or 
more sympathetic neuron-like ones.[18,19,20] Since the 1970’s, this cell line has 
been used as paraneurons – not true neurons, but closely related and sharing 
functions – mainly to study neurotransmitter release; exocytosis.[18,21,22] A 
neuron-like phenotype is often achieved by stimulating the cells with nerve 
growth factor (NGF), the archtypical neurotropic substance. In either form, the 
cells synthesize and store catecholamines (dopamine and sometimes 
norepinephrine), which can then be released through exocytosis.[18,20,23] 
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Exocytocis is normally preceded by internal signalling within a cell, and (local) 
shift in membrane potential (MP); with the opening of voltage-gated Ca
2+
 
channels (VGCCs) intended. By  raising the extracellular KCl concentration and 
thus creating a depolarization (of the entire cell membrane), VGCCs (especially 
N-type and, to a lesser extent, L-type channels) are activated in such PC12 cells 
grown in the presence of NGF, resulting in an influx of Ca
2+
 and leading to 
exocytosis.[24] The resulting in-surge of Ca
2+
 and subsequent resumption of 
normal MP (after vesicle deployment) can potentially be registered by 
voltammetry.[23] 
An even more favourable development – for this intended in vitro-system – would 
be if the cells were enough like neuron that they could be prompted into giving 
off action potentials (APs), or AP-like signals. This could be beneficial because 
the probability of registering such signals ought to be grater, and also because, 
possibly, different signals and their amplitudes would be more uniform. Although, 
as such signals are less sought after in the PC12 cell line, they are both less likely 
to occur and less well proposed how to look for. They have however been 
observed (after electrical stimulation).[25] 
While neurite growth could likely occur, and can be taken for correlation to the 
intended differentiation (which is required for the cells to be able to register and 
respond in the way we are looking to register), the link to the level of symphatetic 
neuron-likeness – neurite sprouting and branching – does not absolutely and 
directly correlate to the responsiveness to KCl, the chosen stimulant. And indeed 
does not guarantee the ability to produce APs (in response to KCl).[20] 
When treated with NGF, PC12 cells stop proliferating (dividing) as they 
differentiate into their neuron-like state. The differentiated cells enter a static G1 
state of their cell cycle, which is why – while proliferation can resume some days 
after discontinued NGF stimulation – they should have been allowed time to fully 
proliferate, approaching confluency, before its addition.[26,27] 
In conclusion, the use of PC12 to model interneurons for the study of signal 
propagation or AP-like signals is not prominent. However, while such signals 
might have been desirable – due to the intended application of the electrodes 
intended for testing, if nothing else – the property demanded from the cells’ 
signals, at this point, is constancy. The so called “release signals” related to the 
initiation of exocytosis could potentially be registered instead. 
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During the course of the project, the cell type was switched to mouse cortical 
stem cells, which are direct precursors to cortical neurons. They should be 
differentiated into very neuron-like states with the help of NGF. 
 
1.5. The Project 
The aim of my project was to set up a quick-stop in vitro test station, at which 
different electrode designs can be tested against one another. (It was also my 
intention to test some of NRC’s electrodes. This aim changed during the course of 
the project.) While cells would have to be grown in advance, and tests scheduled 
in accordance with that supply, the actual testing was to be simple and quick. No 
special training; just enough to familiarize oneself with the equipment and the 
rigid hygiene regulations prescribed within a cell lab. I used an existing setup 
originally assembled for patch clamp experiments. The cell cultures were chosen 
for other experiments primarily. After, and possibly during, the project, I was to 
appreciate the functionality of the current equipment, as well as the cells’ 
suitability.  
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2. Method and Materials 
The equipment I was to work with was a setup the NRC had assembled for patch 
clamp experiments, but which was now unused. The cell cultures were chosen for 
other experiments primarily. While I was to evaluate the usefulness of the existing 
setup, purchasing new equipment would, beyond the high cost, benefit the project 
little, as most relevant apparatuses would take months for delivery. Hence, 
working with what I had, and using a very rough trail-and-error approach, I 
started (see 2.1 The Setup). 
Early on, a practical problem had to be resolved relating to the micromanipulators 
– how are they to hold the electrodes? While this could surely have been done 
several ways; the solution I chose was adequate because it resolved two aspects of 
the problem: how to hold the wire still and how to hold it close to the sample. 
With the help from the NRC workshop I copied the one “holder” (a removable 
plastic piece of which, presumably, there ought to have been two) and held with it 
a glass tube just wide enough to snugly hold the cable to the electrode. This 
allowed for a much better angle of approach, compared to if the cable had been 
held directly at the micromanipulator. This was done for the ground electrode as 
well as the measuring electrode, although it is not of the same importance here (as 
the ground does not need to be finely adjusted). I did, though, want to avoid 
having the ground resting on the edge of the Petri dish, as this could disturb 
(move or shake) the sample. Also, one would want the surroundings of the ground 
and the recording electrodes to be as similar as possible, so the ground too ought 
to rest close to the cells. Movement on the micrometer scale would be of 
significance – a reoccurring problem to solve or factor to consider. The air 
pockets on the table were filled only some time into the experiments, and by then 
the routine was to work around vibrations (e.g. form closing the cage or moving 
about outside) as much as possible. Besides, the cells would move slightly at the 
administration of stimulating solution anyway. 
At this point, the PC12 cells were grown in strict adherence to recommendations 
(cell growth protocol). This included a collagen-IV substrate. The cells did not 
appear to like this, and confluence was far from obtained. Nor did the cells adhere 
well to the substrate, resulting in them being easily dislocated. In fact, the cells 
grew in clumped colonies several layers thick. The cells also did not display any 
significant neurite growth. Interestingly, the cells’ unintended unwillingness to 
form a confluent layer might have been the most useful part of the whole PC12 
endeavor. While this disguised the problem with using the wire electrode type I 
was using at the time (the electrode was much too large compared to the 
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individual cells), it hinted at the possibility of an improved setup using 3D cell 
cultures.  
2.1. The Setup 
To start with, I spent some time getting used to the equipment; the differential 
amplifier, an EX4-400 (Dagan Corporation®), in particular. I read the instruction 
manual to ensure the specifics were (in theory) proper (especially the internal 
impedance). I also read about the data acquisition software – Signal 4 (Cambridge 
Electronic Design (CED)) – and its hardware (Micro 1401 mk II, CED), before 
looking at the background noise (see 2.4. Control measurements). Primarily, I 
attempted to appreciate whether or not the setup’s shielding (a Faraday cage) gave 
adequate reduction of background noise and disturbances from surrounding 
electronic equipment. The cell culture room was in this aspect suboptimal for the 
setup, as nowhere could the cage be placed far from potential sources of noise 
(50Hz wiring in walls and roof, 200Hz fluorescent lights above), although my 
corner was mostly free from electronic equipment (apart from that of the setup, 
which – except the computer screen (see fig.2) – was within the adjacent 
electronics cabinet). I also wanted to further familiarize myself with the amplifier 
and software. This was consequently when I assembled the first, simplest possible 
test-electrode (see 2.5.1. Rudimentary metal electrodes). 
By now, the PC12 cell cultures are up and running. I used my first batch to simply 
look at, as the microscope (Olympus AX70) too required some practice. The 
attached camera made it possible to see and adjust for the small but significant 
dislocations which almost always occurred when one added the KCl to the 
sample. After some tuning, the ancient screen would display enough detail that 
depth could be perceived, although details were never as clear as when looking 
directly via the microscope within the Faraday cage. Unfortunately, I could not 
take pictures using this setup. 
2.1.1. The Faraday cage 
The laboratory room, designed for cell culturing and not for electrophysiological 
measurements, was far from free from potential sources of noise, but the setup 
was of course in a Faraday cage. The electronics cabinet was connected to the 
house's main ground. However, I only later (after the PC12 cell line) connected 
the Faraday cage to the house’s ground wiring. This cut off some additional 
interference, but not enough to reevaluate the entire PC12 setup.  
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Figure 1. The Faraday cage: 
1. C2400 (Hamatsu) real-time observation camera; 
2. Faraday Cage (TMC); 
3. AX70 (Olympus) research system microscope; 
4. Mini 25 (Luigs-Neumann) micromanipulators; 
5. Breadboard (TMC) vibration control table. 
a. IC-200 (PTI) CCD low-light/fluorescence camera. 
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2.1.2. The recording equipment 
 
Figure 2. The recording equipment: 
1. Video monitor (Sanyo); 
2. C2400 (Hamamatsu) camera controller (for Fig.1.1); 
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3.Micro 1401 mk II (Cambridge Electronic Design) data acquisition unit; 
4. Computer screen (NB: outside of cabinet); 
5. Remote Control SM1 (Luigs & Neumann); 
6. EX4-400 (Dagan Corporation) quad differential amplifier; 
7. Computer keyboard and mouse (not in picture: PC); 
8. Shielding electronics cabinet (Rittal CSM ltd). 
a. NeuroLog System (Digimer Ltd); 
b. REGLO-Analogue MS-4/6-100 (IsmaTec) peristalic pump & controller; 
c. TH3 Halogen Light Power Controller (Olympus); 
d. Master-8 (A.M.P.I.) stimulator. 
2.1.3. Miscellaneous equipment 
ISO-Flex (A.M.P.I.) stimulus isolator; 
TDS2002C (Tektronix) oscilloscope; 
MCO-20AIC (Panasonic/Sonyo) cell culture incubator; 
Centrifuge 5810R (Eppendorf). 
 
2.2. The Cell Cultures' Protocols 
I was not the main practitioner of the cell culturing, though I tried my hand at four 
major steps:  
 Flask coating 
 Cell thawing and sowing 
 Cell expansion/proliferation 
 Cell differentiation (subsequent to moving into test receptacle (Petri 
dish)) 
I did not do any cell counting (nor were specific numbers relevant to the project) 
or cryopreservation. The cell culturing followed the same basic format for the two 
cell types. Protocols found in Appendices I and II for PC12 cells and Neural 
cortical stem cells respectively. 
2.2.1 Divergences from the protocols 
PC12 medium used: 86,5% F12-K; 10% Normal Horse Serum; 2.5% Fetal Calf 
Serum; 1% Penicillin-Streptomyicin; 50ng/ml NGF. 
The substrate was changed (from collagen-IV) to poly-L-lysin (PLL; 10 
microgram/ml in distilled H2O) for better cell proliferation and neurite growth. 
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Plates were coated with PLL for 1 hour at 37°C, and rinsed once with distilled 
H2O. 
Towards the end of the project, a cover slip (Thermanox plastic cover slips, Nunc) 
which significantly enhanced the proliferation and differentiation of the cortical 
stem cells was taken into use. The substrate, PLL, remained the same. 
During the last week of the project, due to imminent vacations, there was no time 
to order more Stem Cell Growth Medium (GIBCO), wherefore the last batch of 
cortical stem cells was grown and measured on in Dulbecco’s Modified Eagle 
Medium (GIBCO). This medium has similar if not exactly the same ion 
composition, and I did not alter the applied KCl concentrations (since the 
approximation of the cells receptivity ought to be greater than the difference 
between the mediums’ ionic concentrations). However, there are no registrations 
of note from this batch. 
 
2.3. Potassium Chloride 
KCl was used as stimulating agent throughout the project. This was primarily 
based on a number of sources using it to stimulate PC12 cells (see 1.4 On the 
PC12 Cell Line), along with how an AP emerge due to depolarization in true 
neurons. Note that due to difference in permeability and relation between intra- 
and extracellular concentrations, addition of the same amount of K
+
 and Cl
-
 ions 
will affect the cells MP to higher and lesser degree respectively, causing an 
effective depolarization (in a functioning neuron).  
A too high concentration of KCl added will give an osmotic gradient capable of 
inducing lysis in the cell (i.e. the cells burst from the pressure).  
2.3.1. KCl for PC12 cells 
For the PC12 cells, exactly how similar to neuronal activity one might expect 
them to have was unclear. Exocytosis was possible to achieve in connection to 
AP-like responses to depolarization, according to references. However, whether 
the concentration required for exocytosis was actually appropriate could not be 
elucidated, but most likely an exocytosis inducing concentration would be above 
the one required for AP-like signals. In addition, if the cells were not capable of 
producing such signals, exocytosis associated potential shifts might be registered 
this way.  
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Since the cells progressively lose their functionality when in room temperature 
and lacking CO2 (wrong pH), an estimate is that I needed be done with the 
measurements after a half-hour. Conversely, the cells need be given time to 
respond, and too high osmotic pressure (extracellular ionic concentration) would 
rupture the cells. This is why I add KCl in portions. Ambition was naturally to 
assess a more exact level of stimulant to be administered -- unfortunately, due to 
unresponsive cells throughout, this was not achieved. 
I started out on the PC12 cell using lesser concentrations than the prescribed 
amount, but the finishing total – after three additions – was above. But with the 
lack of response the starting amount was increased, and the end concentration too 
was raised. I started out using 3 times 100µl of 3M KCl, rising to 
(200+100+100)µl for later weeks of PC12 trials.  
2.3.2. KCl for cortical neural stem cells 
Whereas for the PC12 cells I had used a combination of references and trial and 
error, for the cortical stem cells I made the assumption that they were enough like 
neurons that I might calculate an approximate amount of stimulant to add. I 
therefore assume the internal and external concentrations of ions are at natural 
levels. I also say that the volume does not notably change as I add the KCl 
(1000:1 ratio); hence other ion concentrations remain. Under these presumed 
conditions I apply the Nernst equation, referring to the resting potential: 
 -70eV = K   
       
      
   (eq.1) 
Assuming the potassium concentration outside of the cell is 4,5mM, inside the 
cell 140mM, and that the temperature is 37°C (which it will start at): 
 K ≈ 20,36eV 
This can then be used to calculate the (outside) concentration needed to achieve a 
specific MP. As -55 eV is a common threshold value (where an AP might 
emerge) for neurons, that is where I start: 
 [K
+
]out-new =        
   
 ≈ 9,40mM  (eq.2) 
Subtract the amount presumed to already exist in the fluid to arrive at the amount 
which should be added: 
 9,40mM – 4,5mM = 4,9mM 
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The volume this represents is given by: 
 v1* n1 = v2 * n2    (eq.3) 
 v1 * 3M = 10ml * 4,9mM 
 v1 ≈ 16µl 
I used this as a starting point, intending, as before, to more specifically determine 
the amount needed by adding KCl in portions. From the PC12 cells I made the 
assumption the osmotic gradient would not be too disruptive if I went somewhat 
above the calculated amount. I regularly added 16+10+10µl. 
 
2.4. Control Measurements 
I conducted initial background noise level measurements in 0.9% NaCl solution. 
When the cell cultures were on their way, I tried the same in the cell growth 
medium – Ham's F-12K Nutrient Mixture (GIBCO), to ensure the medium itself 
would not be an influential source of noise (already at this point was the growth 
medium, correctly, assumed to be the medium in which recordings were to be 
conducted, since replacing it without disturbing or damaging the cells appeared 
tricky; however, this might have had to do with bad cell adhesion, which was later 
changed). Background noise levels were at this point assessed to be in the region 
of tens of µV, which is acceptable (would not likely drown out AP-like peaks) but 
not excellent. 
Using a stimulus isolator and an oscilloscope I tested the setups basic ability to 
reproduce a distinct signal. This test was conducted several times (after major 
changes -- in setup (electrode) or cell culturing (cell type/medium)). The result 
was good representation with varying loss in amplitude (varying primarily 
dependant on the electrode's impedance).  
 
2.5. Electrodes 
When the project started, the explicit ambition was to test a number of different 
electrode designs on the finished platform. However, due to the slow progress and 
prevailing uncertainty with regards to cell response, the focus was shifted, 
simplified. Consequently, the electrodes used were not the designs currently being 
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developed at the NRC, but ranged from the most basic I could construct to 
purchased products with reliable specifications.  
2.5.1. Rudimentary metal electrodes 
When I started to familiarize myself with the equipment (see 2.1. The Setup) I 
assembled the first, simplest possible test-electrode: a relatively thick (125 µm), 
non-insulated silver wire connected via a shielded cable and BNC connector to 
the amplifier. The prime requirement for this electrode was low impedance (ca 
100kΩ), as to rule it out as a (significant) source of noise. 
From here on, I used the same ground electrode, a (mm) thick silver wire 
connected to the chassis ground of the amplifier with a banana connector. Hence, 
the cable was unshielded.  
The first alteration to make when the recordings proper were to begin was to 
change the electrode to an insulated one. When I at first forgot this, I found the 
recordings all but identical to the noise recordings. I switched to a wire of 
tungsten 33µm with 7µm formvar insulation (the California Fine Wire company). 
The formvar was removed where the wire was to be soldered on, using a scalpel; 
a principally simple procedure yet somewhat tricky to manage without damaging 
or bending (or losing sight of) the thinner-than-hair (well, most human hairs at 
least) metal wire.  
I continuously progressed towards smaller wires, but the smallest wire electrode I 
used before the change to cortical stem cells was 12,5µm, which was yet too 
wide.   
2.5.2. Glass capillaries 
The change from PC12 cells to cortical neural stem cells coincided with the 
revelation that a significantly smaller electrode was needed to record from the 
cells. The individual PC12 cells had all been smaller than the hereto used 
electrodes. Though the cortical cells are larger (approximately 10µm soma width, 
and elongated), this change would still be necessary.  
We opted that a pulled glass capillary with a thin metal (possibly tungsten) wire 
in the center would be a good option. However, it turned out that such a thing is 
not easily produced, and requires special skill (which there was no time for me to 
be taught). There were also no such electrodes ready-made and without 
designation. Hence, we decided I should try using pulled glass capillaries filled 
with a high concentration (3.0M) NaCl solution. I was to produce these glass 
capillaries myself, as the puller was quite simple to work, in principle. Still, it was 
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a bit tricky to get the opening small enough. In addition to taking some time to 
construct, the capillaries were rather delicate, and I dispatched of quite a few in 
the lab, thus needing a few ready before any recording. 
I settled, after testing different settings for different types of glass, for Clark 
Electromedical instruments GC120-15 (i.e. Clark Borosilicate Standard Wall): 
Composition 
80.9% SiO2, 4.4% Na2O, 
12.9% B2O3, 1.8% Al2O3 
Softening 
Temperature 
815°C 
Dielectric 
Constant 
4.7 
 
OD [mm] ID [mm] Wall Thickness [mm] Length [mm] Qty/Pkg Model 
1.2 0.69 0.255 150 350 GC120-15 
Approximate settings on the puller: Heat, 80; pull, 110 or max; jerk, 15. Most 
capillaries still required some grinding of the tip; it was quite tricky to blindly 
grind the exact amount needed for µm precision. 
At first, I approximated the opening needed be, at most, about 5µm wide. 
However, this turned out to be too wide. Secondly, I managed to go to 4µm, or 
just below; which was significantly more difficult. Quite soon, it appeared 
apparent that < 3µm or so was a necessary size to get down to. However, when I, 
after some effort, managed to produce a few of these; it turned out the 1-2µm 
capillaries had too high impedance. At this point I considered the endeavor too 
time-consuming, and I continued using the TRec electrodes (2.5.3).  
2.5.3. Manufactured quartz/metal microelectrodes 
Before I had the level of practice needed to continuously and efficiently produce 
thin glass capillaries, I was borrowed two units of a reliable, manufactured and 
well tested type of electrode. These were quartz-glass covered pulled metal 
(platinum/tungsten) with an opening of a few µm and an impedance of around 
1,5±0,3MΩ (ThomasRecording). 
 
 
Figure 3 Schematic pictures of the electrode and its tip. The connector is gold-plated male, the 
protective tubing quartz. (Thomas Recording, Single Electrode Product Information.) 
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The specifications, including the impedance and tip size, are quite viable in the 
setup, and the recordings presented in the following part (3. Results and 
Discussion) were made using this electrode type. 
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3. Results and Discussion 
The results are not given in quantitative form because I did not arrive at such. To 
make this section more productive I shall hence try to interweave the results, such 
as they are, with introspection and discussion. 
 
3.1. The PC12 Cell Line 
While the PC12 cells were grown on a collagen substrate, they did not do well, 
and appeared as seen in Figure 4. They did not approach confluence, and they did 
not appear to differentiate. Observe the prominence of clusters of cells; cells 
seemingly prefer to grow atop one another rather than on the substrate.  
 
Figure 4. PC12 cells grown for two days in vitro (without NGF) 
The change of substrate increased proliferation and the ability to grow neurites. 
The change was almost as drastic as the difference between Figure 4 and Figure 
5. After this change, the cells were used after three to six days exposure to NGF, 
when further confluency had been achieved.   
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Figure 5. Two images of PC12 cells grown with NGF for two days in vitro 
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A too high concentration of KCl added will give an osmotic gradient capable of 
inducing lysis in the cell (i.e. the cells burst from the pressure). This limit was 
reached, and since registrations still were not made, a stricter reevaluation of the 
basic approach would perhaps have been beneficial.  However, a lowering of the 
NaCl (changing growth medium to a "measuring medium") could have been one 
way forward; yet the extra procedure was never fully investigated, but was 
considered a needless extra feature as the cells were not required to survive 
anyway, and since they did not burst immediately. Alternatively, electrical 
stimulation rather than chemical could have been tested. 
Throughout the recordings from the PC12 cells, only one recording stood out. At 
that time, I had entered a particularly large cluster of cells, to the extent and effect 
that recording and ground electrode did not measure from the same environment.  
Remember however that the clusters were of seemingly undifferentiated PC12 
cells, that I had at this point not yet grounded all the equipment properly, and the 
lab table did not have gas suspension. Movement outside the cage could be 
registered, and subsequent registrations make this most likely. The random nature 
of the event increases the likelihood it was an outside disturbance. 
As I mentioned earlier, however, theses clusters illustrated the possibility of an 
improved setup using 3D cell cultures. A 3D structure would be much more 
influential, and possibly required, when using the intended electrodes.  Electrodes 
that the setup is intended for are meant for chronic implantation in a real, 3D 
brain, and thus are not ideal for measuring from a 2D surface with, and different 
designs might be affected by this to different degrees, which could be decisive. 
Would electrical stimulation have been preferable? Will KCl only have the 
potential to induce exocytosis, and will then such an event be “loud” enough to be 
registered? Quite likely there is a reason this is not a cell type often used to study 
APs.  
 
3.2. The Cortical Stem Cell Line 
The cells looked good from the beginning, differentiating well, yet proliferation 
was later improved and confluency went from 60-70% to 80-90% (rough 
estimate). A 90-100% confluent monolayer is depictured in Figure 6 (image from 
supplier of the cryopreserved cells). 
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Figure 6. Mouse cortical neural stem cells [Figure 1a, Catalog No. SCR029, Chemicon® 
International] 
From the shape, duration, and lack of similar peaks at the baseline, it is reasonable 
to assume the cortical cells are responsible for the peak in Figure 7. Based on 
shape and amplitude (reasonable for an extracellular recording), such a peak is 
considered an AP. The peaks also reoccur with increasing time-spans in-between 
(refractory times), and with slightly decreasing amplitudes. This too is reasonable 
for APs.  
 
Figure 7. Recording of possible AP 
In Figure 8, the peaks reoccur in a pattern which suggests that two cells might be 
firing. The time-span between the two peaks in Figure 8 is approximately 20ms, 
and the two peaks reoccur several times at 15-20s intervals. This interval was 
consistent whether for one or two peaks (12-20s, varying more between than 
within samples). 
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Figure 8. Possible recording of APs (signal amplified x10) 
The amount of KCl needed to achieve AP-like responses was consistently 36µl, 
added in three batches (see 2.3.2. KCl for cortical neural stem cells). The time it 
took for the cells to respond after the third KCl-addition varied, between 10 and 
90s. 
 
3.3. Possible Improvements of the Setup 
Due to the slim angle of access allowed between the microscope and the Petri 
dish’s rim along with the slim nature of the single, confluent layer of cells 
obtained with the cortical cells (and late with the PC12 cells), a part of the 
electrode will always be atop the cells, measuring against the background, 
lowering the signal-to-noise ratio. 
Is the way to counter this problem the use of 3D cellular assays? These would 
further mimic the intended environment – a living brain – which is certain to be a 
good thing, is it not? Well, while 3D assays are full of potential, they are also less 
well studied, and less simple to produce. A good and consistent implementation 
could certainly have the potential to further the in vitro-system’s merit, however.  
One aspect which would have to be assessed is whether or not a (chemical) 
stimulating agent (e.g. KCl) would be able to spread – (somewhat) evenly – 
throughout such an assay. If only the outer/upper layer(s) is affected, little or 
nothing has improved – unless perhaps one uses the recording electrode to 
stimulate the cells. 
With the open top – for easy access – solution, stability in the cell cultures system 
will only be maintained for a short time; as I have already argued, this 
accessibility is a significant part of the setup.  
A closed system and a heated, CO2-profused sample holder – necessarily in 
connection to an inverted microscope – would be a huge investment for dubious 
gain. Even with a closed system, the contamination risks are high, and sample 
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might have to be discarded. It is also questionable whether one could get more 
from a sample than – like now – two or three opportunities. The cells will be 
exhausted, and the medium would have to be changed after tests, at the least. 
 
3.4. Evaluation of the Project 
During the PC12 experiments, I used levels of KCl high enough to potentially 
induce exocytosis. I arrived at those concentrations in steps. The osmotic gradient 
produced was damaging enough to the cells that some burst, limiting time and 
amount of cells from which to register. A medium with adjusted ionic levels 
(lowered Na
+
, heightened K
+
) is normally used in exocytosis experiments, but the 
change was deemed problematic here. This was about to be reevaluated, but 
instead the cell type was changed. This should be considered again, should PC12 
cells be approached anew.  
Possibly, there was a problem with cell adhesion, which too early on tainted the 
flexibility of the process. Once the cells were grown properly, exchanging the 
growth medium for phosphate buffered saline might well have been plausible. If 
so, greater pH-buffering ability would have been obtained, and life expectancy for 
the exposed cells prolonged.  
The ideal time for measurements on a cell batch was not (empirically) quantified, 
but from assessing the PC12 cells based on appearance, I defined the window of 
opportunity as being between three days and six days differentiated with NGF. 
Shorter and they are still differentiating, longer and the terminally differentiated 
cells might even have started breaking down (possibly reducing responsiveness in 
cells yet alive).  
When working with PC12 cells at least, the choice to continue using KCl as a 
stimulating agent for long might have been a mistake. At least attempting 
electrical stimulation would have been beneficial. Also, the choice of KCl level 
based on the levels required for exocytosis (and then raising the amount when no 
registrations appeared) might also have been a less favorable choice. Although the 
cells lasted long enough (before the osmotic pressure caused them to swell and 
sometimes burst) that they ought to have had time to respond to the treatment, 
were they at all able to begin with. However, I cannot, based on my project, see a 
reason one would choose PC12 cells for a similar setup.  
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Whether or not the cells were responsive ought to have been investigated in some 
way other than electronic registration. Fluorescent markers for displaying calcium 
influx might have been one such approach. 
When working with the cortical stem cells registrations of apparent APs were at 
least achieved. Given more time, one could have brought this setup further, for 
example assessing more exactly the necessary KCl-level.  The problem with 
narrowing down the stimulating agents volume span is the (presumed) variability 
between individual cells (we measure from just one, maybe two or a few cells at 
any time). To frequently reach above the cells’ individual thresholds, an excess 
amount is readily used. Maybe the prolonged use of each sample demands too 
much? One can prolong the effective lifespan by introducing new equipment (e.g. 
CO2-profusion). Yet the potential economical gain is offset by the investment in 
new equipment, and the scientific gain (heightened performance reliability) might 
be insignificant if appropriate considerations (particularly concerning the timing 
aspect) are taken; all preparations made and the procedure well practiced. Also, 
remember that the basic idea for this setup was for it to be quick and simple to 
use. 
There was a lack of structure throughout the project, and more trial and error than 
ought be. This led not only to some very basic mistakes (mainly early on; e.g. the 
use of an almost definitely too large electrode), but also to an ineffective use of 
time. With more forethought, and more early expert input to catch basic flaws, the 
project might have had a lot better flow. My inexperience in the lab also limited 
my ability to perform as consistently as one would like, yet as I felt progress, a 
more experienced lab worker would likely find the procedures basic. This might 
be enough to make the setup viable.  
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4. Conclusions 
I can not say – based on this project – that the setup can be considered an 
effective quick-assessment station for comparing fresh electrodes (intended for 
implantation). If an in vitro test is to be useful, higher level of consistency in 
response from the cells is a minimum requirement. 
With the open top – for easy access – solution, stability in the cell cultures system 
will only be maintained for a short time; as I have already argued, this 
accessibility is a significant part of the setup. A closed system and a heated, CO2-
profused sample holder – necessarily in connection to an inverted microscope – 
would be a huge investment for dubious gain.  
If the system is to be pursued in an as simple form as possible – yet with some 
merit; unlike the current version – the transition to 3D-assays along with a more 
narrowly specified amount of stimulating agent are priorities. If a good use of the 
cells can be maintained, a subsequent step might be to add an open-top heated 
sample holder, as to more accurately and for longer maintain the cells’ 
responsiveness. However, all “improvements” are meaningless unless the cells 
can be made to consistently give off AP-like signals. During the project, I’ve seen 
hints that this could be achieved – for mouse neural cortical stem cells – but I 
cannot say that it as of yet has.  
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Appendix I 
 
I.I: Preparing PC12 cell medium 
Materials 
1. F12-K medium (Gibco) 
2. Fetal calf serum (Gibco) 
3. Normal Horse serum (Gibco) 
4. Pen strep (Gibco) 
 
Procedure 
1. Preparation of PC 12 medium (Preparation of 100 mL) 
a. 86,5 mL F12-K Medium 
b. 10 mL (10%) Normal Horse Serum 
c. 2,5 mL (2.5%) Fetal Calf Serum 
d. 1 mL (1%) Pen/strep - antibiotics 
 
 
I . II:  Thawing of  PC 12  cel ls  
Materials 
1. Frozen Cells 
2. PC12 medium 
3. T75 flask 
4. 15 mL centrifuge tube 
 
Procedure 
 
1. Prepare a 15 mL vial with 10 mL medium (10 mL medium/vial). 
2. Thaw the cells rapidly in a 37°C waterbath by swirling the vial in the water until 
only a small ump of ice remains. 
3. Centrifuge at 300 g for 3 min. 
4. Discard supernatant. 
5. Resuspend the pellet in 10 mL medium 
a. After this step you may take a sample for cell counting and viability 
check. 
6. Add the cell suspension to the T75 flask. 
7. Determine the cell attachment after 24 h post-thaw. 
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I.III: Splitting PC 12 cells 3 to 1 in T75 flasks. 
Materials 
5. PC 12 cells in a T75 Flask 
6. Accutase, (Millipore) 
7. 15 mL centrifuge tube. 
8. F12 
9. Fetal calf serum 
10. Normal Horse serum 
11. Pen strep 
 
Procedure 
1. Prepare 50 mL PC12 medium accordning to protocol. Keep at room temperature 
(RT). 
2. Remove all media from flask.  
3. Add 3 mL 37°C Accutase to the flask and place it in the incubator at 37°C for 
approx 3-5 minutes. 
4. Pipet the Accutase solution approx 5 times inside the flask and place the cell 
suspension in a 15 mL conical centrifuge tube. Add approx 7 mL PC12 media. 
5. Wash the cells by centrifugation at 400 rcf for 5 min. at 4°C. 
6. Decant the supernatant and resuspend the cell pellet in 30 mL PC 12 media. 
7. Add 10 mL of cell suspension to each flasks. 
8. Place the flasks in an incubator at 37°C, 5% CO2 . 
9. Change media every 3-4 days. 
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I.IV: Cryopreservation of PC 12 cells 
Materials 
12. PC 12 cells in a T75 Flask 
13. Accutase, (Millipore) 
14. Recovery™ Cell Culture Freezing Medium 
15. Cool Cell 
16. Dry ice 
17. Dewar 
18. 1 mL cryotubes 
 
Procedure 
1. Remove all media from the flask.  
2. Add 3 mL 37°C Accutase to the flask and place it in the incubator at 37°C for 
approx 3-5 minutes. 
3. Pipet the Accutase solution approx 5 times in the flask and place the cell 
suspension in a 15 mL conical centrifuge tube. Add approx 7 mL PC12 media. 
4. Wash the cells by centrifugation at 300 rcf for 3 min. at 4°C. 
5. Decant the supernatant. 
6. Resuspend the cells in 3 mL Recovery freezing medium. Keep on ice. 
7. Add 1 mL of cell suspension to each cryotube. 
8. Place the cryotubes with cells in Cool Cell kept on dry ice and then place the 
Cool Cell at -80ºC in a freezer over night. 
9. Store the cryotubes at -80°C. 
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Appendix II 
EMD Millipore: 
NEURAL STEM CELL BASAL MEDIUM  
CATALOG NUMBER:   SCM003 
http://www.millipore.com/publications.nsf/a73664f9f981af8c852569b9005b4eee/
a65321c3f0d3b54c852576dd0081e1cc/$FILE/SCM003.pdf 
 
EMD Millipore: 
CRYOPRESERVED MOUSE CORTICAL NEURSL STEM CELLS   
CATALOG NUMBER:   SCR029 
http://www.millipore.com/userguides.nsf/a73664f9f981af8c852569b9005b4eee/6
7e27f0a0f6b56cd8525791e00686fb7/$FILE/SCR029.pdf 
 
